Asunaprevir (Asunaprevir, formerly BMS-650032 , trade name in Japan and Russia [1] Sunvepra ) is an inhibitor of the NS3 serine protease enzyme of the hepatitis C virus [2] , II wave I generation. It does not have FDA registration, but is officially registered in the Russian Federation: it is used as part of the interferon-free regimen of hepatitis C genotype 1 (genotype 1b to a greater extent and 1a to a lesser extent) in combination with daclatasvir and sofosbuvir . Produced by . In Japan, for the treatment of genotype 1, the Ximency preparation was registered [3] as part of / daclatasvir / asunaprevir.
| Asunaprevir | |
|---|---|
 | |
| Chemical compound | |
| Gross formula | C 35 H 46 ClN 5 O 9 S |
| CAS | |
| Pubchem | |
| Drugbank | |
Notes
- ↑ Sunvepra ™ (asunaprevir) in soft capsules, 100 mg. Registration certificate . State register of medicines . The appeal date is January 23, 2016.
- ↑ C. Reviriego. Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus (Eng.) // Drugs of the Future: journal. - 2012. - Vol. 37 , no. 4 - P. 247-254 . - DOI : 10.1358 / dof.2012.37.4.1789350 .
- ↑ KEGG DRUG: New Drug Approvals in Japan . www.genome.jp. The date of circulation is July 20, 2017.